BEIJING, China – Israeli wastewater treatment firm Emefcy is continuing its international expansion by partnering with construction and engineering company, China Gezhouba Group Investment Holding (CGGC INV).
The partnership will start with the deployment of a 20 m3/day demonstration plant using the company’s Membrane Aerated Biofilm Reactor (MABR) in Jingmen, Hubei Province.
The two companies are then planning to jointly bid onan initial 345 rural wastewater treatment plants of varying capacity from 50 m3/day to 200 m3/day in two key districts in Hebei.
Subject to the satisfactory performance of the demonstration plant, the second phase will see CGGC INV commit to purchase at least 10,000 MABR modules in the first year.
If this goes through, Emefcy said it would build a dedicated production line in China to support the deployments.
News of the China partnership helped to push the company’s share price up on the Australian Securities Exchange by 2%.
Earlier this year the Israeli company signed its first international contact in Ethiopia (read story).
The MABR technology is a spirally-wound sleeve with an internal air-side spacer, through which low pressure air is blown. The spiral is submerged in a tank to which wastewater is fed continuously and effluent is discharged by overflow.
According to the company, this saves energy by “eliminating the need to blow compressed air into the depth of the water for aeration, through the implementation of Emefcy's patented passive aeration process”.
Song Ling, chairman, CGGC INV, said: “Following successful deployments, we also anticipate partnering with Emefcy to offer scalable treatment solutions around the world.”
Richard Irving, executive chairman of Emefcy, said: “This is an important partnership with a leading Chinese engineering company which is anticipating to receive the largest allocation of rural wastewater treatment plants from the Chinese government.”
###
Read more
Emefcy inaugurates first municipal MABR wastewater project in Israel
Ethiopia MABR wastewater deal marks international expansion for Emefcy
